State Initiatives to Control Medication Costs--Can Transparency Legislation Help?
From the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.
Ameet
A
Sarpatwari
From the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.
Jerry
J
Avorn
From the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.
Aaron S
AS
Kesselheim
D003363:Cost Control; D016527:Drug Costs; D055808:Drug Discovery / Q000191:economics* / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D033161:Government Regulation; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000191:economics; D055553:Prescription Drugs / Q000191:economics*; D013219:State Government; D014481:United States
D055553:Prescription Drugs